CenterBook Partners LP Sells 4,791 Shares of Cencora, Inc. (NYSE:COR)

CenterBook Partners LP decreased its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 26.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,573 shares of the company's stock after selling 4,791 shares during the period. CenterBook Partners LP's holdings in Cencora were worth $3,050,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new stake in shares of Cencora in the 4th quarter worth $67,000. Renaissance Technologies LLC lifted its stake in Cencora by 140.6% in the 4th quarter. Renaissance Technologies LLC now owns 550,700 shares of the company's stock valued at $123,731,000 after buying an additional 321,800 shares in the last quarter. Twin Capital Management Inc. increased its position in Cencora by 18.0% during the 4th quarter. Twin Capital Management Inc. now owns 14,148 shares of the company's stock worth $3,179,000 after purchasing an additional 2,162 shares in the last quarter. Invesco Ltd. raised its stake in Cencora by 20.4% in the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after purchasing an additional 550,246 shares during the last quarter. Finally, Bank of Montreal Can lifted its holdings in Cencora by 30.5% in the 4th quarter. Bank of Montreal Can now owns 296,033 shares of the company's stock valued at $66,513,000 after purchasing an additional 69,142 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Bank of America raised their price objective on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday. Evercore ISI raised their price target on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Finally, Wells Fargo & Company upped their price target on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $284.20.

Remove Ads

Insiders Place Their Bets

In related news, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now directly owns 14,665 shares in the company, valued at $3,934,326.20. The trade was a 21.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,675 shares of company stock worth $8,034,778 over the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Cencora Price Performance

Shares of COR traded down $0.41 on Tuesday, hitting $283.88. The company's stock had a trading volume of 298,352 shares, compared to its average volume of 1,503,450. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The company has a market capitalization of $55.05 billion, a PE ratio of 40.38, a PEG ratio of 1.31 and a beta of 0.55. The company has a 50 day moving average price of $260.88 and a 200 day moving average price of $245.57. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $296.65.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were given a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.77%. Cencora's dividend payout ratio is 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.